Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

Published:2013-05-22 Issue:4 Volume:27 Page:293-304
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Sullivan-Chang Loretta,O’Donnell Robert T.,Tuscano Joseph M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-013-0016-7.pdf

Reference84 articles.

1. Walker JA, Smith KGC. CD22: an inhibitory enigma. Immunology. 2008;123(3):314–25.

2. Engel P, Wagner N, Miller AS, Tedder TF. Identification of the ligand-binding domains of the CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med. 1995;181:1581–6.

3. Otipoby KL, Draves KE, Clark EA. CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem. 2001;276(47):44315–22.

4. Fujimoto M, Kuwano Y, Watanabe R, et al. B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol. 2006;176:873–9.

5. Gross AJ, Lyandres JR, Panigrahi AK, Prak ET, DeFranco AL. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J Immunol. 2009;182(9):5382–92.

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From mechanism to therapy: the journey of CD24 in cancer;Frontiers in Immunology;2024-05-31

2. Unveiling the hub genes in the SIGLECs family in colon adenocarcinoma with machine learning;Frontiers in Genetics;2024-04-08

3. Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma;Cancers;2024-02-18

4. An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia;International Journal of Biological Macromolecules;2024-01

5. Gradation control in the hydrodynamic diameters of mixed glycan-aglycan glycovesicles;Pure and Applied Chemistry;2023-07-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3